Gefitinib and erlotinib are first-generation (1G) reversible EGFR-TKIs that are highly effective against NSCLC carrying common activating EGFR mutations (exon 19 deletion or exon 21 L858R) [4–8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.